2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Prof Ian Smith MD, Marion Procter MSci, Prof Richard D Gelber PhD, Sébastien Guillaume MSc, Andrea Feyereislova MD, Prof Mitch Dowsett PhD, Prof Aron Goldhirsch MD, Prof Michael Untch MD, Gabriella Mariani MD, Prof Jose Baselga MD, Prof Manfred Kaufmann MD, David Cameron MD, Prof Richard Bell MD, Prof Jonas Bergh MD, Prof Robert Coleman MD, Andrew Wardley MD, Prof Nadia Harbeck MD, Roberto I Lopez MD, Prof Peter Mallmann MD, Prof Karen Gelmon MD, Nicholas Wilcken PhD, Prof Erik Wist PhD, Pedro Sánchez Rovira MD, Prof Martine J Piccart-Gebhart MD, for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. The Lancet 2007; 369: 29-36.
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
Emilio Alba, Manuel Ruiz-Borrego, Mireia Margelí, Álvaro Rodríguez-Lescure, Pedro Sánchez-Rovira, Amparo Ruiz, Jose Ramón Mel-Lorenzo, Manuel Ramos-Vázquez, Nuria Ribelles, Elisa Calvo, Antonio Casado, Antonia Márquez, David Vicente, José Angel García-Sáenz and Miguel Martín. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Research and Treatment 2010; 122 (1): 169.
Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study
Antón , A. Ruiz, M. A. Seguí, L. Calvo, M. Muñoz, J. Lao, F. Sancho and L. Fernández. Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Annals of Oncology 2009; 20(3):454-459.
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
G Estévez L, Fortes JL, Adrover E, Peiró G, Margel M, Castellá E, Cuevas JM, Bernet L, Seguí MA, Andreu X. Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. Clinical & Translational Oncology 2009; 11(1):54-59
Molecular Predictors of Efficacy of Adjuvant Weekly Paclitaxel in Early Breast Cancer.
Miguel Martin, Álvaro Rodríguez-Lescure, Amparo Ruiz, Emilio Alba, Lourdes Calvo, Manuel Ruiz-Borrego, Ana Santaballa, Cesar A. Rodríguez, Carmen Crespo, Mar Abad, Severina Dominguez, Jesús Florián, Cristina Llorca, Miguel Méndez, Maria Godes, Ricardo Cubedo, Adolfo Murias, Norberto Batista, Maria Jose Garcia, Rosalia Caballero and Enrique de Álava. Molecular Predictors of Efficacy of Adjuvant Weekly Paclitaxel in Early Breast Cancer. Breast Cancer Research and Treatment 2009; 123(1):149-157.
|
|
